»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Àڱ󻸷Áõ Ä¡·áÁ¦ ½ÃÀåÀº 2024-2029³â 4¾ï 5,790¸¸ ´Þ·¯ Áõ°¡Çϰí, ¿¹Ãø ±â°£ Áß ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 4.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àڱ󻸷Áõ Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇÑ ÀüüÀûÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ ´ë»óÀ¸·Î ÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ °ÔÀçÇß½À´Ï´Ù.
ÇöÀçÀÇ ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ¼ºÀå¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº Áúº´ À¯º´·ü Áõ°¡¿Í Áø´Ü ÆÐ·¯´ÙÀÓÀÇ °³¼±, źźÇÑ ÀÓ»ó ÆÄÀÌÇÁ¶óÀΰú Ä¡·á¹ý Çõ½Å, ¿ËÈ£ Ȱµ¿ÀÇ È®´ë, Á¤ºÎ Áö¿ø, ÇコÄɾî ÅõÀÚ Áõ°¡¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ
2025³â
Á¾·á ¿¬µµ
2029³â
¿¹Ãø ±â°£
2025-2029³â
¼ºÀå ¸ð¸àÅÒ
°¡¼Ó
Àü³â´ëºñ
4.2%
CAGR
4.3%
Áõ°¡¾×
4¾ï 5,790¸¸ ´Þ·¯
ÀÌ Á¶»ç´Â ¾÷°è ÁÖ¿ä Âü°¡ÀÚÀÇ ÀǰßÀ» Æ÷ÇÔÇÏ¿© 1Â÷ ¹× 2Â÷ Á¤º¸¸¦ °´°üÀûÀ¸·Î °áÇÕÇÏ¿© ¼öÇàµÇ¾ú½À´Ï´Ù. ÀÌ º¸°í¼¿¡´Â ÁÖ¿ä ±â¾÷ ºÐ¼®, Á¾ÇÕÀûÀÎ ½ÃÀå ±Ô¸ð µ¥ÀÌÅÍ, Áö¿ªº° ºÐ¼®¿¡ µû¸¥ ºÎ¹®, °ø±Þ¾÷ü ÇöȲÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. º¸°í¼¿¡´Â °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅͰ¡ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â ÇâÈÄ ¸î ³â°£ Àڱ󻸷Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ÀÌÀ¯ Áß Çϳª·Î ºñÈ£¸£¸ó Ä¡·á °æ·Î·ÎÀÇ Àü·«Àû ÀüȯÀ» ²Å¾Ò½À´Ï´Ù. ¶ÇÇÑ, µðÁöÅÐ °Ç° »ýŰèÀÇ ÅëÇÕ, °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ Ãß±¸, ÃÑüÀûÀÌ°í ´ÙÇÐÁ¦ÀûÀÎ Ä¡·á ÇÁ·¹ÀÓ¿öÅ©ÀÇ Ã¤ÅÃÀº ½ÃÀåÀÇ Å« ¼ö¿ä¸¦ âÃâÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå Technavio ºÐ¼®
°¡°Ý, ¼ö¸íÁÖ±â, °í°´ ±¸ÀÔ ¹Ù½ºÄÏ, äÅà ºñÀ², ±¸ÀÔ ±âÁØ ºÐ¼®
ÀÎDzÀÇ Á߿伺°ú Â÷º°È ¿äÀÎ
È¥¶õ ¿äÀÎ
¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
Á¦3Àå ½ÃÀå ±¸µµ
½ÃÀå »ýŰè
½ÃÀå Æ¯Â¡
¹ë·ùüÀÎ ºÐ¼®
Á¦4Àå ½ÃÀå ±Ô¸ð
½ÃÀåÀÇ Á¤ÀÇ
½ÃÀå ºÎ¹® ºÐ¼®
½ÃÀå ±Ô¸ð(2024³â)
½ÃÀå Àü¸Á(2024-2029³â)
Á¦5Àå ½ÃÀå ±Ô¸ð ½ÇÀû
¼¼°èÀÇ Àڱ󻸷Áõ Ä¡·áÁ¦ ½ÃÀå(2019-2023³â)
Á¦Ç°º° ºÎ¹® ºÐ¼®(2019-2023³â)
Åõ¿© °æ·Îº° ºÎ¹® ºÐ¼®(2019-2023³â)
À¯Åë ä³Îº° ºÎ¹® ºÐ¼®(2019-2023³â)
Áö¿ªº° ºÎ¹® ºÐ¼®(2019-2023³â)
±¹°¡º° ºÎ¹® ºÐ¼®(2019-2023³â)
Á¦6Àå Á¤¼º ºÐ¼®
AIÀÇ ¿µÇâ : ¼¼°èÀÇ Àڱ󻸷Áõ Ä¡·áÁ¦ ½ÃÀå
Á¦7Àå Five Forces ºÐ¼®
Five Forces ¿ä¾à
¹ÙÀ̾îÀÇ ±³¼··Â
°ø±Þ ±â¾÷ÀÇ ±³¼··Â
½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
´ëüǰÀÇ À§Çù
°æÀï À§Çù
½ÃÀå ÇöȲ
Á¦8Àå ½ÃÀå ¼¼ºÐÈ : Á¦Ç°º°
½ÃÀå ºÎ¹®
ºñ±³ : Á¦Ç°º°
È£¸£¸ó ¿ä¹ý : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÁøÅëÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : Á¦Ç°º°
Á¦9Àå ½ÃÀå ¼¼ºÐÈ : Åõ¿© °æ·Îº°
½ÃÀå ºÎ¹®
ºñ±³ : Åõ¿© °æ·Îº°
°æ±¸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÁÖ»çÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : Åõ¿© °æ·Îº°
Á¦10Àå ½ÃÀå ¼¼ºÐÈ : À¯Åë ä³Îº°
½ÃÀå ºÎ¹®
ºñ±³ : À¯Åë ä³Îº°
¼Ò¸Å ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
º´¿ø ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¿Â¶óÀÎ ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : À¯Åë ä³Îº°
Á¦11Àå °í°´ »óȲ
Á¦12Àå Áö¿ªº° »óȲ
Áö¿ªº° ¼¼ºÐÈ
Áö¿ªº° ºñ±³
ºÏ¹Ì : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
À¯·´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¾Æ½Ã¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¼¼°è ±âŸ Áö¿ª : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¹Ì±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Áß±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¿µ±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
µ¶ÀÏ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ij³ª´Ù : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÀϺ» : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Àεµ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÇÁ¶û½º : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
È£ÁÖ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Çѱ¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : Áö¿ª »óȲº°
Á¦13Àå ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ ¹× ¼ºÀå ¾ïÁ¦¿äÀÎ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
½ÃÀå ±âȸ¿Í ¼ºÀå ¾ïÁ¦¿äÀÎ
Á¦14Àå °æÀï ±¸µµ
°³¿ä
°æÀï ±¸µµ
ÆÄ±«Àû Çõ½Å »óȲ
¾÷°è ¸®½ºÅ©
Á¦15Àå °æÀï ºÐ¼®
±â¾÷ °³¿ä
±â¾÷ ¼øÀ§ Áö¼ö
±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×
AbbVie Inc.
Bayer AG
Debiopharm International SA
Enteris BioPharma Inc.
Gedeon Richter Plc
Johnson and Johnson Services Inc.
Kissei Pharmaceutical Co. Ltd.
Neurocrine Biosciences Inc.
Nippon Shinyaku Co. Ltd.
Novartis AG
Organon and Co.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Á¦16Àå ºÎ·Ï
LSH
The endometriosis drugs market is forecasted to grow by USD 457.9 mn during 2024-2029, accelerating at a CAGR of 4.3% during the forecast period. The report on the endometriosis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing disease prevalence and improved diagnostic paradigms, robust clinical pipeline and innovation in therapeutic modalities, and expanding advocacy, favourable government initiatives, and increased healthcare investment.
Market Scope
Base Year 2025
End Year 2029
Series Year 2025-2029
Growth Momentum Accelerate
YOY 2025 4.2%
CAGR 4.3%
Incremental Value $457.9 mn
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's endometriosis drugs market is segmented as below:
By Product
Hormone therapy
Analgesics
By Route Of Administration
By Distribution Channel
Retail pharmacy
Hospital pharmacy
Online pharmacy
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)
This study identifies the strategic pivot to non-hormonal therapeutic pathways as one of the prime reasons driving the endometriosis drugs market growth during the next few years. Also, integration of digital health ecosystems and pursuit of personalized medicine and adoption of holistic and multidisciplinary care frameworks will lead to sizable demand in the market.
The report on the endometriosis drugs market covers the following areas:
Endometriosis Drugs Market sizing
Endometriosis Drugs Market forecast
Endometriosis Drugs Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading endometriosis drugs market vendors that include AbbVie Inc., Ananda Pharma, Bayer AG, Debiopharm International SA, Enteris BioPharma Inc., Gedeon Richter Plc, Gesynta Pharma AB, Hope Medicine, Johnson and Johnson Services Inc., Kissei Pharmaceutical Co. Ltd., Neurocrine Biosciences Inc., Nippon Shinyaku Co. Ltd., Novartis AG, Organon and Co., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viramal Ltd. Also, the endometriosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market By Geographical Landscape
Executive Summary - Chart on Market Segmentation by Product
Executive Summary - Chart on Market Segmentation by Route of Administration
Executive Summary - Chart on Market Segmentation by Distribution Channel
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
Overview on factors of disruption
2.4 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
3.1 Market ecosystem
Parent Market
Data Table on - Parent Market
3.2 Market characteristics
Market characteristics analysis
3.3 Value chain analysis
4 Market Sizing
4.1 Market definition
Offerings of companies included in the market definition
4.2 Market segment analysis
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
Chart on Global - Market size and forecast 2024-2029 ($ million)
Data Table on Global - Market size and forecast 2024-2029 ($ million)
Chart on Global Market: Year-over-year growth 2024-2029 (%)
Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
5.1 Global Endometriosis Drugs Market 2019 - 2023
Historic Market Size - Data Table on Global Endometriosis Drugs Market 2019 - 2023 ($ million)
5.2 Product segment analysis 2019 - 2023
Historic Market Size - Product Segment 2019 - 2023 ($ million)
5.3 Route of Administration segment analysis 2019 - 2023
Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
5.4 Distribution Channel segment analysis 2019 - 2023
Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
5.5 Geography segment analysis 2019 - 2023
Historic Market Size - Geography Segment 2019 - 2023 ($ million)
5.6 Country segment analysis 2019 - 2023
Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
6.1 The impact of AI in the global Endometriosis Drugs market
7 Five Forces Analysis
7.1 Five forces summary
Five forces analysis - Comparison between 2024 and 2029
7.2 Bargaining power of buyers
Bargaining power of buyers - Impact of key factors 2024 and 2029
7.3 Bargaining power of suppliers
Bargaining power of suppliers - Impact of key factors in 2024 and 2029
7.4 Threat of new entrants
Threat of new entrants - Impact of key factors in 2024 and 2029
7.5 Threat of substitutes
Threat of substitutes - Impact of key factors in 2024 and 2029
7.6 Threat of rivalry
Threat of rivalry - Impact of key factors in 2024 and 2029
7.7 Market condition
Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Product
8.1 Market segments
Chart on Product - Market share 2024-2029 (%)
Data Table on Product - Market share 2024-2029 (%)
8.2 Comparison by Product
Chart on Comparison by Product
Data Table on Comparison by Product
8.3 Hormone therapy - Market size and forecast 2024-2029
Chart on Hormone therapy - Market size and forecast 2024-2029 ($ million)
Data Table on Hormone therapy - Market size and forecast 2024-2029 ($ million)
Chart on Hormone therapy - Year-over-year growth 2024-2029 (%)
Data Table on Hormone therapy - Year-over-year growth 2024-2029 (%)
8.4 Analgesics - Market size and forecast 2024-2029
Chart on Analgesics - Market size and forecast 2024-2029 ($ million)
Data Table on Analgesics - Market size and forecast 2024-2029 ($ million)
Chart on Analgesics - Year-over-year growth 2024-2029 (%)
Data Table on Analgesics - Year-over-year growth 2024-2029 (%)
8.5 Market opportunity by Product
Market opportunity by Product ($ million)
Data Table on Market opportunity by Product ($ million)
9 Market Segmentation by Route of Administration
9.1 Market segments
Chart on Route of Administration - Market share 2024-2029 (%)
Data Table on Route of Administration - Market share 2024-2029 (%)
9.2 Comparison by Route of Administration
Chart on Comparison by Route of Administration
Data Table on Comparison by Route of Administration
9.3 Oral - Market size and forecast 2024-2029
Chart on Oral - Market size and forecast 2024-2029 ($ million)
Data Table on Oral - Market size and forecast 2024-2029 ($ million)
Chart on Oral - Year-over-year growth 2024-2029 (%)
Data Table on Oral - Year-over-year growth 2024-2029 (%)
9.4 Injectables - Market size and forecast 2024-2029
Chart on Injectables - Market size and forecast 2024-2029 ($ million)
Data Table on Injectables - Market size and forecast 2024-2029 ($ million)
Chart on Injectables - Year-over-year growth 2024-2029 (%)
Data Table on Injectables - Year-over-year growth 2024-2029 (%)
9.5 Others - Market size and forecast 2024-2029
Chart on Others - Market size and forecast 2024-2029 ($ million)
Data Table on Others - Market size and forecast 2024-2029 ($ million)
Chart on Others - Year-over-year growth 2024-2029 (%)
Data Table on Others - Year-over-year growth 2024-2029 (%)
9.6 Market opportunity by Route of Administration
Market opportunity by Route of Administration ($ million)
Data Table on Market opportunity by Route of Administration ($ million)
10 Market Segmentation by Distribution Channel
10.1 Market segments
Chart on Distribution Channel - Market share 2024-2029 (%)
Data Table on Distribution Channel - Market share 2024-2029 (%)
10.2 Comparison by Distribution Channel
Chart on Comparison by Distribution Channel
Data Table on Comparison by Distribution Channel
10.3 Retail pharmacy - Market size and forecast 2024-2029
Chart on Retail pharmacy - Market size and forecast 2024-2029 ($ million)
Data Table on Retail pharmacy - Market size and forecast 2024-2029 ($ million)
Chart on Retail pharmacy - Year-over-year growth 2024-2029 (%)
Data Table on Retail pharmacy - Year-over-year growth 2024-2029 (%)
10.4 Hospital pharmacy - Market size and forecast 2024-2029
Chart on Hospital pharmacy - Market size and forecast 2024-2029 ($ million)
Data Table on Hospital pharmacy - Market size and forecast 2024-2029 ($ million)
Chart on Hospital pharmacy - Year-over-year growth 2024-2029 (%)
Data Table on Hospital pharmacy - Year-over-year growth 2024-2029 (%)
10.5 Online pharmacy - Market size and forecast 2024-2029
Chart on Online pharmacy - Market size and forecast 2024-2029 ($ million)
Data Table on Online pharmacy - Market size and forecast 2024-2029 ($ million)
Chart on Online pharmacy - Year-over-year growth 2024-2029 (%)
Data Table on Online pharmacy - Year-over-year growth 2024-2029 (%)
10.6 Market opportunity by Distribution Channel
Market opportunity by Distribution Channel ($ million)
Data Table on Market opportunity by Distribution Channel ($ million)
11 Customer Landscape
11.1 Customer landscape overview
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
12.1 Geographic segmentation
Chart on Market share By Geographical Landscape 2024-2029 (%)
Data Table on Market share By Geographical Landscape 2024-2029 (%)
12.2 Geographic comparison
Chart on Geographic comparison
Data Table on Geographic comparison
12.3 North America - Market size and forecast 2024-2029
Chart on North America - Market size and forecast 2024-2029 ($ million)
Data Table on North America - Market size and forecast 2024-2029 ($ million)
Chart on North America - Year-over-year growth 2024-2029 (%)
Data Table on North America - Year-over-year growth 2024-2029 (%)
12.4 Europe - Market size and forecast 2024-2029
Chart on Europe - Market size and forecast 2024-2029 ($ million)
Data Table on Europe - Market size and forecast 2024-2029 ($ million)
Chart on Europe - Year-over-year growth 2024-2029 (%)
Data Table on Europe - Year-over-year growth 2024-2029 (%)
12.5 Asia - Market size and forecast 2024-2029
Chart on Asia - Market size and forecast 2024-2029 ($ million)
Data Table on Asia - Market size and forecast 2024-2029 ($ million)
Chart on Asia - Year-over-year growth 2024-2029 (%)
Data Table on Asia - Year-over-year growth 2024-2029 (%)
12.6 Rest of World (ROW) - Market size and forecast 2024-2029
Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
12.7 US - Market size and forecast 2024-2029
Chart on US - Market size and forecast 2024-2029 ($ million)
Data Table on US - Market size and forecast 2024-2029 ($ million)
Chart on US - Year-over-year growth 2024-2029 (%)
Data Table on US - Year-over-year growth 2024-2029 (%)
12.8 China - Market size and forecast 2024-2029
Chart on China - Market size and forecast 2024-2029 ($ million)
Data Table on China - Market size and forecast 2024-2029 ($ million)
Chart on China - Year-over-year growth 2024-2029 (%)
Data Table on China - Year-over-year growth 2024-2029 (%)
12.9 UK - Market size and forecast 2024-2029
Chart on UK - Market size and forecast 2024-2029 ($ million)
Data Table on UK - Market size and forecast 2024-2029 ($ million)
Chart on UK - Year-over-year growth 2024-2029 (%)
Data Table on UK - Year-over-year growth 2024-2029 (%)
12.10 Germany - Market size and forecast 2024-2029
Chart on Germany - Market size and forecast 2024-2029 ($ million)
Data Table on Germany - Market size and forecast 2024-2029 ($ million)
Chart on Germany - Year-over-year growth 2024-2029 (%)
Data Table on Germany - Year-over-year growth 2024-2029 (%)
12.11 Canada - Market size and forecast 2024-2029
Chart on Canada - Market size and forecast 2024-2029 ($ million)
Data Table on Canada - Market size and forecast 2024-2029 ($ million)
Chart on Canada - Year-over-year growth 2024-2029 (%)
Data Table on Canada - Year-over-year growth 2024-2029 (%)
12.12 Japan - Market size and forecast 2024-2029
Chart on Japan - Market size and forecast 2024-2029 ($ million)
Data Table on Japan - Market size and forecast 2024-2029 ($ million)
Chart on Japan - Year-over-year growth 2024-2029 (%)
Data Table on Japan - Year-over-year growth 2024-2029 (%)
12.13 India - Market size and forecast 2024-2029
Chart on India - Market size and forecast 2024-2029 ($ million)
Data Table on India - Market size and forecast 2024-2029 ($ million)
Chart on India - Year-over-year growth 2024-2029 (%)
Data Table on India - Year-over-year growth 2024-2029 (%)
12.14 France - Market size and forecast 2024-2029
Chart on France - Market size and forecast 2024-2029 ($ million)
Data Table on France - Market size and forecast 2024-2029 ($ million)
Chart on France - Year-over-year growth 2024-2029 (%)
Data Table on France - Year-over-year growth 2024-2029 (%)
12.15 Australia - Market size and forecast 2024-2029
Chart on Australia - Market size and forecast 2024-2029 ($ million)
Data Table on Australia - Market size and forecast 2024-2029 ($ million)
Chart on Australia - Year-over-year growth 2024-2029 (%)
Data Table on Australia - Year-over-year growth 2024-2029 (%)
12.16 South Korea - Market size and forecast 2024-2029
Chart on South Korea - Market size and forecast 2024-2029 ($ million)
Data Table on South Korea - Market size and forecast 2024-2029 ($ million)
Chart on South Korea - Year-over-year growth 2024-2029 (%)
Data Table on South Korea - Year-over-year growth 2024-2029 (%)
12.17 Market opportunity By Geographical Landscape
Market opportunity By Geographical Landscape ($ million)
Data Tables on Market opportunity By Geographical Landscape ($ million)
13 Drivers, Challenges, and Opportunity/Restraints
13.1 Market drivers
13.2 Market challenges
13.3 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
13.4 Market opportunities/restraints
14 Competitive Landscape
14.1 Overview
14.2 Competitive Landscape
Overview on criticality of inputs and factors of differentiation
14.3 Landscape disruption
Overview on factors of disruption
14.4 Industry risks
Impact of key risks on business
15 Competitive Analysis
15.1 Companies profiled
15.2 Company ranking index
15.3 Market positioning of companies
Matrix on companies position and classification
15.4 AbbVie Inc.
AbbVie Inc. - Overview
AbbVie Inc. - Product / Service
AbbVie Inc. - Key news
AbbVie Inc. - Key offerings
SWOT
15.5 Bayer AG
Bayer AG - Overview
Bayer AG - Business segments
Bayer AG - Key news
Bayer AG - Key offerings
Bayer AG - Segment focus
SWOT
15.6 Debiopharm International SA
Debiopharm International SA - Overview
Debiopharm International SA - Product / Service
Debiopharm International SA - Key news
Debiopharm International SA - Key offerings
SWOT
15.7 Enteris BioPharma Inc.
Enteris BioPharma Inc. - Overview
Enteris BioPharma Inc. - Product / Service
Enteris BioPharma Inc. - Key offerings
SWOT
15.8 Gedeon Richter Plc
Gedeon Richter Plc - Overview
Gedeon Richter Plc - Business segments
Gedeon Richter Plc - Key offerings
Gedeon Richter Plc - Segment focus
SWOT
15.9 Johnson and Johnson Services Inc.
Johnson and Johnson Services Inc. - Overview
Johnson and Johnson Services Inc. - Business segments
Johnson and Johnson Services Inc. - Key news
Johnson and Johnson Services Inc. - Key offerings
Johnson and Johnson Services Inc. - Segment focus
SWOT
15.10 Kissei Pharmaceutical Co. Ltd.
Kissei Pharmaceutical Co. Ltd. - Overview
Kissei Pharmaceutical Co. Ltd. - Product / Service
Kissei Pharmaceutical Co. Ltd. - Key offerings
SWOT
15.11 Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc. - Overview
Neurocrine Biosciences Inc. - Product / Service
Neurocrine Biosciences Inc. - Key offerings
SWOT
15.12 Nippon Shinyaku Co. Ltd.
Nippon Shinyaku Co. Ltd. - Overview
Nippon Shinyaku Co. Ltd. - Product / Service
Nippon Shinyaku Co. Ltd. - Key offerings
SWOT
15.13 Novartis AG
Novartis AG - Overview
Novartis AG - Business segments
Novartis AG - Key news
Novartis AG - Key offerings
Novartis AG - Segment focus
SWOT
15.14 Organon and Co.
Organon and Co. - Overview
Organon and Co. - Product / Service
Organon and Co. - Key offerings
SWOT
15.15 Pfizer Inc.
Pfizer Inc. - Overview
Pfizer Inc. - Product / Service
Pfizer Inc. - Key news
Pfizer Inc. - Key offerings
SWOT
15.16 Sanofi SA
Sanofi SA - Overview
Sanofi SA - Business segments
Sanofi SA - Key news
Sanofi SA - Key offerings
Sanofi SA - Segment focus
SWOT
15.17 Takeda Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Co. Ltd. - Overview
Takeda Pharmaceutical Co. Ltd. - Product / Service
Takeda Pharmaceutical Co. Ltd. - Key news
Takeda Pharmaceutical Co. Ltd. - Key offerings
SWOT
15.18 Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. - Overview
Teva Pharmaceutical Industries Ltd. - Business segments
Teva Pharmaceutical Industries Ltd. - Key news
Teva Pharmaceutical Industries Ltd. - Key offerings
Teva Pharmaceutical Industries Ltd. - Segment focus
SWOT
16 Appendix
16.1 Scope of the report
16.2 Inclusions and exclusions checklist
Inclusions checklist
Exclusions checklist
16.3 Currency conversion rates for US$
Currency conversion rates for US$
16.4 Research methodology
16.5 Data procurement
16.6 Data validation
16.7 Validation techniques employed for market sizing
Validation techniques employed for market sizing
16.8 Data synthesis
16.9 360 degree market analysis
360 degree market analysis
16.10 List of abbreviations